New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
16:12 EDTCORTCorcept Therapeutics reports Q4 estimated net revenue of $1.4M
Consensus is $1.49M
News For CORT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 13, 2015
19:35 EDTCORTCorcept announces results of Phase 1/2 mifepristone/eribulin study
Corcept Therapeutics, a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, announced results of a multi-center Phase 1/2 dose-escalation study of mifepristone and chemotherapy drug eribulin, or Halaven, that show it is well tolerated and clinically active in patients with triple-negative breast cancer. These results were published in the 2015 American Society of Clinical Oncology, ASCO, Annual Meeting Program. Corcept CEO Joseph Belanoff said. "If our Phase 1/2 demonstrates efficacy, we plan to begin a Phase 3 study in early 2016. We are also developing compounds from our portfolio of next-generation selective GR antagonists. We hope to advance our lead compound, CORT125134, to a Phase 2 study for the treatment of a second oncology indication early next year."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use